Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5463_Библиотеки_им_академика_М_И_Перельмана.pdf
8
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
l
c
is the critical nonpolar group length, V
group, and a
0
FIGURE 1.3
Source
TABLE 1.1
Molecules in the Micelles, Bilayers, and Vesicles (Mahale et al., 2012).
CPP Type of aggregation
Less than 0.35
0.35–0.4
0.4–0.55
0.55–0.6
0.6–0.85
0.85–0.95
0.95–1.15
More than 1.15
Micelles can be spherical or cylindrical
Flexible bilayers, vesicles, and cylindrical micelles
Bilayers that are malleable
Micelles that have been reversed
Niosomes in Delivery of Therapeutics and Biomedical Application
9
1.2 APPLICATIONS OF NIOSOME
-
and transmucosal delivery, including proteins, peptides, anticancer drugs,
can entrap both hydrophilic and hydrophobic molecules in the vesicles and
1.2.1 NIOSOMAL FORMULATIONS FOR VARIOUS ADMINISTRATIVE
ROUTES
various routes.
-
nous (IV), (2) intramuscular (IM), and (3) subcutaneous (SC).
the IV route as it enters the systemic circulation immediately and has the
10
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
cally active, cheaper, and in addition to that, niosomes are naturally biode-
cyanoacrylate-co
three carcinomatous cell lines (KB, K562, and S180 cells), the greatest intra-
cellular uptake, particularly in nuclei, the highest tumor concentration and
-
IV administration (Ali et al., 2018). Minamisakamoto et al. (2021) prepared
to improve antitumor activity in mice bearing Colon-26 cancer cells (C26).
niosome (Minamisakamoto et al., 2021).
-
have been designed. Murdan and group have prepared niosomes using
sorbitan monostearate and cholesteryl-polyoxyethylene ether, and hemag-
Niosomes in Delivery of Therapeutics and Biomedical Application
11
in-vivo
-
et al., 2015).
are made to overcome the natural obstacles to insulin uptake in the skin,
2009).
-
in-vivo study suggested that the niosomes could prolong the drug release
cholesterol to overcome hypersensitivity, anaphylactic reactions, and pain.
In-vivo pharmacokinetic characteristics (rat model) revealed the relatively
12
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
stability in the gastrointestinal tract and poor absorption, thus resulting in
used such as liposomes, quantum dots (QDs), micelles, and nanoparticles.
-
in-vivo
Niosomes in Delivery of Therapeutics and Biomedical Application
13
-
niosomes as promising carriers to enhance the oral bioavailability and solu-
in-vitro
®
Fathalla et al. (2020) prepared niosome-based gel systems using Span 40
14
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
eye drops (Fathalla et al., 2020). Allam and group prepared pH-triggered
-
®
-
such as asthma, chronic obstructive pulmonary disease, and various types
Niosomes in Delivery of Therapeutics and Biomedical Application
15
-
-
-
cytotoxicity in a human lung cancer cell line (A549). Hence, niosomes have
niosome demonstrated the high potential as promising nanoparticulate
parameters and bioavailability (Ammar et al., 2017). Chitosan-coated
-
to p
due to nonchanging physicochemical properties. Hence, CS-niosome-loaded
16
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
2020). Stable niosomes using Span 60 and cholesterol by incorporating
administration (Arendt and Skene, 2005). A transmucosal niosome melatonin
absorption and systemic circulation, implying that the transmucosal MN gel
-
compliance. Best gelation temperature (31°C), viscosity (1250 mpoise),
2
1.2.2 NIOSOMES FOR THE DELIVERY OF THERAPEUTICS
Niosomes in Delivery of Therapeutics and Biomedical Application
17
and peptides to the deceased cells (Sadeghi et al., 2019).
-
normal lung (MRC5) and lung cancer (A549) cell lines revealed that the
-